down arrow

Xeris Biopharma Holdings, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98422E1038
USD
6.72
0.25 (3.86%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Xeris Biopharma Holdings, Inc.
Nuvation Bio, Inc.
uniQure NV
Humacyte, Inc.
23andMe Holding Co.
MeiraGTx Holdings Plc
Terns Pharmaceuticals, Inc.
ProKidney Corp.
Seres Therapeutics, Inc.
Zura Bio Ltd.
Renovaro, Inc.
Why is Xeris Biopharma Holdings, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 13.86% of over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
2
With a growth in Operating Profit of 599.84%, the company declared Very Positive results in Jun 25
  • The company has declared positive results for the last 2 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -16.17 MM
  • NET SALES(Q) Highest at USD 71.54 MM
  • RAW MATERIAL COST(Y) Fallen by -1.85% (YoY)
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 130.52%, its profits have risen by 30.3%
4
High Institutional Holdings at 65.86%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Consistent Returns over the last 3 years
  • Along with generating 130.52% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Xeris Biopharma Holdings, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Xeris Biopharma Holdings, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Xeris Biopharma Holdings, Inc.
96.49%
3.34
61.63%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
110.17%
EBIT Growth (5y)
13.86%
EBIT to Interest (avg)
-5.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.05
Sales to Capital Employed (avg)
0.86
Tax Ratio
5.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
65.86%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-20.88
EV to EBIT
-40.50
EV to EBITDA
-91.67
EV to Capital Employed
6.40
EV to Sales
4.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-15.80%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

29What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -16.17 MM

NET SALES(Q)

Highest at USD 71.54 MM

RAW MATERIAL COST(Y)

Fallen by -1.85% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 5.15 times

OPERATING PROFIT(Q)

Highest at USD 7.65 MM

OPERATING PROFIT MARGIN(Q)

Highest at 10.69 %

PRE-TAX PROFIT(Q)

Highest at USD -1.93 MM

NET PROFIT(Q)

Highest at USD -1.93 MM

EPS(Q)

Highest at USD -0.01

-2What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 117.72 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.99 times

Here's what is working for Xeris Biopharma Holdings, Inc.
Operating Cash Flow
Highest at USD -16.17 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 71.54 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit
At USD -1.93 MM has Grown at 84.16%
over average net sales of the previous four periods of USD -12.17 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD -1.93 MM has Grown at 83.27%
over average net sales of the previous four periods of USD -11.53 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales
At USD 71.54 MM has Grown at 28.58%
over average net sales of the previous four periods of USD 55.64 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 7.65 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 10.69 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD -1.93 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -1.93 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.01
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debtors Turnover Ratio
Highest at 5.15 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -1.85% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 3.16 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Xeris Biopharma Holdings, Inc.
Cash and Eqv
Lowest at USD 117.72 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 0.99 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."